New Jersey is currently home to 1696 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
NCT07012993
Recruiting
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Alzheimer's disease, mild cognitive impairment, other forms of dementia detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-Florbetapir or 18F-Flutemetamo... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/01/2025
Locations: Nuclear Imaging Institute, Englewood, New Jersey
Conditions: Healthy Volunteer, Alzheimer's Disease, Mild Cognitive Impairment, Other Forms of Dementia
Register for Updates
Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
NCT07012642
Recruiting
Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: River Center, Red Bank, New Jersey
Conditions: Lymphedema
Register for Updates
Ultralow Dose PET Imaging of 18F-FDG Uptake
NCT06956391
Recruiting
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDG and be imaged on a new type of high-sensitivity PET scanner for up to 3 hours.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/01/2025
Locations: Nuclear Imaging Institute, Englewood, New Jersey
Conditions: Healthy Volunteer, Cancer
Register for Updates
Ultralow Dose PET Imaging for PSMA Expression
NCT06904313
Recruiting
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for prostate cancer detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-DCFPyL and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/01/2025
Locations: Nuclear Imaging Institute, Englewood, New Jersey
Conditions: Healthy Volunteer, Prostate CA
Register for Updates
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
NCT05079282
Recruiting
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Relapsed or Refractory T Cell Lymphoma
Register for Updates
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: Hackensack University Medical Center - John Theurer Cancer, Hackensack, New Jersey
Conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Register for Updates
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
NCT07011004
Recruiting
The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with relapsed/refractory acute myelogenous leukemia (AML). The researchers will also look at whether the treatment combination works against participants' cancer.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/30/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Register for Updates
A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease
NCT06810960
Recruiting
The primary purpose of this study is to evaluate safety of lecanemab in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in participants treated with lecanemab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Eisai Trial Site #1, Nutley, New Jersey
Conditions: Alzheimer's Disease
Register for Updates
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
NCT06668324
Recruiting
The study aims to compare the experiences, including injection-related reactions (IRRs) of patients newly receiving ofatumumab to those starting to receive ocrelizumab SC formulation
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/30/2025
Locations: Novartis Investigative site, East Hanover, New Jersey
Conditions: Multiple Sclerosis
Register for Updates
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Home-based telemedicine, Trenton, New Jersey
Conditions: Chronic Granulomatous Disease (CGD)
Register for Updates
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
NCT06575192
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of ARTIA in adult participants undergoing immediate, two-stage, implant-based breast reconstruction post-mastectomy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Rutgers New Jersey Medical School - Newark /ID# 264187, Newark, New Jersey
Conditions: Breast Reconstruction
Register for Updates
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613
Recruiting
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a humanized T cell engaging bispecific antibody targeting CLDN6, in subjects with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Context Investigational Site, Hackensack, New Jersey
Conditions: Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Register for Updates